An indirect treatment comparison shows that dupilumab and tezepelumab yield broadly similar clinical benefits in patients ...

The National Institute for Health and Care Excellence (NICE) has published final draft guidance recommending dupilumab as an ...

Please provide your email address to receive an email when new articles are posted on . Dupilumab is approved for atopic dermatitis in children aged 6 months and older. Patients on dupilumab did not ...

A new study published in the journal of Pediatric Dermatology revealed that treatment with dupilumab achieved effective ...

BOSTON -- Add-on dupilumab (Dupixent) significantly reduced itching and urticaria in patients with chronic spontaneous urticaria (CSU) whose symptoms were uncontrolled with H1-antihistamine therapy.

Compared with dupilumab, a significantly higher proportion of patients treated with upadacitinib achieved both EASI 90 and WP-NRS 0/1 at week 16. Among patients with moderate to severe atopic ...

Please provide your email address to receive an email when new articles are posted on . Incidence rates for cancers included 12.88 for the exposed group and 15.04 for the unexposed group. Adjusting ...

ORLANDO -- Among children taking the monoclonal antibody dupilumab (Dupixent) for atopic dermatitis, more than a quarter of ocular complications developed after a year, according to a retrospective ...

These improvements — as measured by a significantly lower annualized rate of acute exacerbations, significantly better lung function and quality of life, and significantly less severe symptoms than ...

Chronic obstructive pulmonary disease patients with type 2 inflammation may soon gain access to a new drug — dupilumab — that showed rapid and sustained improvements in patients in a pivotal Phase 3 ...